Story perspectives

FDA Approves First OTC Tylenol-Naproxen Pain Combo

7/25/2026

Summary

FDA Approves Tylenol

The U.S. FDA approved Tylenol® with Naproxen, the first OTC combo of 650 mg acetaminophen and 220 mg naproxen sodium, for pain relief.
Eight clinical studies found the combination gives superior pain relief versus acetaminophen or naproxen alone.
A March 2026 Kenvue survey (n=6,240) reported 75 % of persistent-pain sufferers are dissatisfied with current options.
Dr. Rajesh Mishra said the product simplifies pain management, received a three-year exclusivity, and will soon be sold nationwide.

Summary

Kenvue Launches Tylenol

Kenvue Brands LLC announced Tylenol® with Naproxen as an opioid-free OTC pain reliever.
The product offers a prescription-strength-equivalent alternative to help address the opioid crisis.
Kenvue’s release includes forward-looking statements and directs investors to its Form 10-K for the fiscal year ended December 28 2025 and Form 10-Q reports for risk factors.
The announcement notes Aleve is a Bayer Healthcare LLC trademark, indicating competition with established NSAID brands.

Summary

Paxton Sues Tylenol

Texas Attorney General Ken Paxton sued Kenvue, reviving a 2025 case that said the company failed to warn about a possible Tylenol-autism link for pregnant women.
A U.S. appeals court recently revived over 500 private lawsuits asserting similar autism-risk claims against Tylenol.
In 2025, President Donald Trump and health officials urged pregnant women to stop using Tylenol, citing an unproven autism link despite medical groups deeming it safe.

1 of 3

FDA Approves Tylenol

The U.S. FDA approved Tylenol® with Naproxen, the first OTC combo of 650 mg acetaminophen and 220 mg naproxen sodium, for pain relief.
Eight clinical studies found the combination gives superior pain relief versus acetaminophen or naproxen alone.
A March 2026 Kenvue survey (n=6,240) reported 75 % of persistent-pain sufferers are dissatisfied with current options.
Dr. Rajesh Mishra said the product simplifies pain management, received a three-year exclusivity, and will soon be sold nationwide.

1 / 3